Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthBlue Cross Blue Shield NV TMS Coverage Prior Auth …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NevadaPolicy N/A

    Transcranial Magnetic Stimulation (TMS) request form and coverage criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nevada policy alerts

    Know when Blue Cross Blue Shield - Nevada releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a payer request/authorization form and associated coverage guidance for TMS treatment requests submitted to Blue Cross Blue Shield - Nevada; it governs pre-authorization submission content and clinical screening for members seeking TMS for depressive and other neuropsychiatric conditions.

    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyTranscranial Magnetic Stimulation (TMS) request form and coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit a completed TMS request form with documentation of at least two adequate pharmacotherapy trials, standardized depression rating scores, device used, and requested number of sessions for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30standard acute-course maximum sessions (over ~6 weeks)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    week taper schedule length (3,2,1 sessions)
    18+minimum age for depressive disorder TMS requests
    Theta burst stimulationstated as not medically necessary for all indications

    Coverage Criteria for TMS

    Initial TMS for MDD

    Covered when ALL of the following are met for Depressive Disorder requests:

    Adult diagnosis and TRD: Individual is 18 years or older AND has a confirmed diagnosis of treatment-resistant major depressive disorder (single or recurrent episode).

    from form checkboxes

    Prior pharmacotherapy trials: Individual has had an inadequate response to pharmacotherapy despite adequate duration and dosage, documented adherence, and trials from 2 or more classes of medications OR documented inability to tolerate pharmacotherapy with 2 trials showing side effects.2 medication classes

    documented on form

    Device and administration: TMS will be administered by a U.S. FDA-approved device for the treatment of MDD with specified stimulation parameters according to the manufacturer's user manual; device must be specified on the form if used.

    form checkbox

    Treatment course limits: Standard treatment course will not exceed 5 days per week for 6 weeks (total 30 sessions), followed by a 3-week taper of 3, 2, and 1 sessions respectively.30 sessions + 3-week taper

    form specifies schedule

    Exclusions - seizure and psychosis: Individuals with a seizure disorder or history of seizure (except ECT-induced or isolated febrile seizures in infancy without recurrence) OR individuals with acute or chronic psychotic symptoms/disorders in the current depressive episode are excluded from coverage for TMS.

    checkbox exclusions on form

    Exclusions - neurological conditions: Individuals with specified neurological conditions (epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, primary or secondary CNS tumors) are excluded or require caution per the form.

    form lists neurological exclusions

    The request form and coverage guidance include specific caveats and contraindications to ensure safe candidate selection for transcranial magnetic stimulation (TMS). The form identifies that individuals with a history of seizure disorder or prior seizure (except ECT-induced or isolated febrile seizures in infancy without recurrence), active acute or chronic psychotic symptoms or disorders during the current depressive episode, or certain neurological conditions (for example epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, severe/repetitive head trauma, or CNS tumors) are excluded from routine TMS coverage unless otherwise addressed. The form also requires screening for current use of substances that may significantly lower seizure threshold and documents implanted magnetic-sensitive medical devices located within ≤ 30 centimeters of the TMS coil (for example cochlear implants, ICDs, pacemakers, VNS, deep brain stimulators, or metal aneurysm clips/coils/staples/stents) as contraindications or situations requiring special consideration.

    Theta burst stimulation (TBS) is explicitly listed on the form as not medically necessary for all indications. Requests for TBS may therefore be denied. Providers must use the standard TMS parameters with FDA‑approved devices per manufacturer instructions and document device type when submitting an authorization request.

    Providers submitting authorization materials should include the completed form with standardized depression rating scale scores, medication trial history, dates/doses/duration and adherence documentation, the specified FDA-approved device (if applicable), and the requested start date and number of sessions to allow review against these caveats.

    Theta burst stimulation (TBS) is considered not medically necessary for all indications. The request form contains this explicit statement and indicates that requests for TBS may be denied.

    Billing and Coding

    Covered CPT Codes (form lists for authorization request)CPT
    90867Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management
    90868Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
    90869Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management
    Standard acute treatment course — session frequency and taper schedule
    Session frequencyUp to 5 days per week for up to 6 weeks (standard acute course)
    Maximum sessions (acute)Total of 30 sessions over the 6-week acute course
    Taper schedule3-week taper: 3 sessions in week 1, 2 sessions in week 2, and 1 session in week 3

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for transcranial magnetic stimulation (TMS) services. Submit a completed Transcranial Magnetic Stimulation Request form to assist with timely review. Fax completed form to 866-834-7469 (toll-free). Include the member name, ID number, DOB, requesting provider information (physician name, provider NPI, tax ID), and requested start date and number of sessions/units.

    • Affected services: TMS for major depressive disorder (see request form)
    • Fax: 866-834-7469
    Documentation Required

    Pharmacotherapy Trial Documentation

    Document trials of pharmacotherapy for the current or prior depressive episode. The request must show inadequate response to pharmacotherapy despite: adequate dose and duration, documented adherence, and trials from two or more distinct medication classes. If pharmacotherapy could not be tolerated, document at least two trials with documented side effects and intolerance. Provide dates, maximum dose, duration, outcome, side-effects, adherence, and other relevant details for each medication trial.

    Definitions

    Retreatment — definition and contextual note
    DefinitionRetreatment: prior response to TMS defined by ≥50% reduction in symptom severity on a standardized rating scale AND recurrence of depression shown by clinically meaningful worsening relative to best TMS response on a standardized rating scale.
    Authorization noteIf request is for retreatment, provide prior authorization number for the previous treatment when available.
    ContextRetreatment applies when prior clinical benefit from TMS was documented and symptoms have recurred; the form requires documentation of prior response and recurrence using standardized scales.
    Maintenance treatment — definition including remission timeframe
    DefinitionMaintenance treatment: treatment that continues after remission has been achieved; remission is the virtual absence of depressive symptoms for at least 3 weeks.
    Remission timeframe

    Background and Purpose

    This form is used to collect the clinical information necessary to assess the appropriateness of transcranial magnetic stimulation (TMS) for members, with a primary focus on adults with treatment‑resistant major depressive disorder (MDD). It gathers standardized depression rating scale scores (initial and final with dates), confirmation of age and diagnosis, documentation of prior pharmacotherapy trials (including dates, doses, duration, outcomes, and adherence), safety screening for seizure risk and implanted magnetic‑sensitive devices, and the TMS device to be used when applicable.

    The form also captures treatment intent (initial acute course, retreatment, continuation, or maintenance) and specifies the expected standard acute TMS course: up to 5 days per week for 6 weeks (total of 30 sessions) followed by a 3-week taper (3, 2, then 1 session). This information supports prior authorization review and aligns submitted requests with coverage criteria for TMS in treatment‑resistant MDD.

    Level of Care Criteria

    Treatment Modalities

    TMS

    TMS modality: Therapeutic repetitive TMS for MDD using a U.S. FDA-approved device administered per manufacturer parameters; theta burst stimulation is explicitly listed as not medically necessary and is not covered.

    form items; CPT codes listed for TMS delivery and management

    Visit Limits and Session Limits

    TMS visit limits — up to 30 sessions plus a 3-week taper (3,2,1 sessions)
    Total session limitUp to 30 sessions during the standard acute course (6 weeks)
    Taper period3-week taper after the acute course: 3 sessions, then 2 sessions, then 1 session
    Typical course lengthInitial acute course approximately 6 weeks plus the 3-week taper period
    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyTranscranial Magnetic Stimulation (TMS) request form and coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit a completed TMS request form with documentation of at least two adequate pharmacotherapy trials, standardized depression rating scores, device used, and requested number of sessions for prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for TMSBilling and CodingProvider Actions and Documentation RequirementsDefinitionsBackground and PurposeLevel of Care CriteriaTreatment ModalitiesVisit Limits and Session Limits
    • Require documentation of ≥2 medication classes tried with adequate dose/duration and adherence
    • If intolerance is cited, provide ≥2 trials with documented adverse effects
    Documentation Required

    Required Submission Documents

    Required submission documents: a fully completed TMS request form including UM # (if received), member identifiers (name, ID #, DOB, current age), diagnosis and standardized rating scale initial and final scores with dates, specific TMS device (if used), requested start date and number of sessions/units, and requesting provider contact information (physician name, phone, fax, provider NPI, tax ID). For retreatment requests, include the prior authorization number if available and documentation showing prior response (≥50% reduction on a standardized rating scale) and recurrence.

    • Completed Transcranial Magnetic Stimulation Request form (all sections)
    • Standardized rating scales with initial and final scores and dates
    • Provider NPI and Tax ID; physician signature and date
    • If retreatment: prior auth number and documentation of prior response
    Documentation Required

    Optional Supporting Documentation

    Optional supporting documentation may be submitted to strengthen the request. This includes a copy of the TMS intake evaluation or a full psychiatric evaluation performed within three months prior to the requested start of treatment, and any additional clinical notes describing treatment history, suicide risk assessment, or functional impairment.

    • TMS intake evaluation or full psychiatric evaluation within 3 months of requested start date (optional)
    • Any additional clinical records relevant to treatment history
    Denial Risk

    Denial Risk — Insufficient Prior Medication Trials

    Insufficient documentation of prior medication trials may result in denial. Requests lacking clear evidence of trials from two or more medication classes, adequate dose/duration, or documented adherence (or documented intolerance as specified) are at risk for denial as not meeting medical necessity criteria.

    • Denial risk if medication trial details (dates, doses, duration, adherence, outcomes) are missing or incomplete
    Remission defined as virtual absence of depressive symptoms for at least 3 weeks.
    ContextMaintenance is distinct from continuation or retreatment and may end with either relapse or recovery.
    Continuation treatment — definition and duration (up to 6 months)
    DefinitionContinuation treatment: a course that begins after the acute/index course and lasts up to 6 months to prevent worsening of symptoms for an episode that has not yet remitted.
    Maximum durationUp to 6 months following the acute/index course when clinically necessary.
    PurposeDesigned to prevent symptom worsening during an ongoing depressive episode that has not achieved remission.